Biopharmaceutical News and Research

RSS

Insmed second quarter revenues decrease to $1.0 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2011.

8 Aug 2011

Keryx reports net loss of $3.1 million for second quarter 2011

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease, today announced its results for the second quarter ended June 30, 2011.

8 Aug 2011

Micromet second quarter total revenues increase to $7.1 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

SynCo Bio commences release of drug products after expansion of Class A zone

SynCo Bio Partners B.V., one of the leading GMP contract manufacturers of biopharmaceuticals today announced that its aseptic filling facility is again fully operational and SynCo has produced and released the first drug product batches for its clients after the expansion of its Class A zone.

4 Aug 2011

Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.

4 Aug 2011

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.

3 Aug 2011

Insmed receives FDA clinical hold order for ARIKACE phase 3 trials in CF and NTM

Insmed Incorporated, a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on Insmed's phase 3 clinical trials for ARIKACE in Cystic Fibrosis (CF) patients with Pseudomonas lung infections and patients with non-tuberculous mycobacterial (NTM) lung disease.

2 Aug 2011

Auxilium second quarter net loss decreases to $5.1 million

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended June 30, 2011. For the second quarter of 2011, Auxilium reported net revenues of $65.9 million compared to net revenues of $50.5 million in the second quarter of 2010.

1 Aug 2011

Vanda, Biotoscana Farma partner to commercialize Fanapt in Argentina

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Argentina-based Biotoscana Farma S.A., a wholly owned affiliate of Biotoscana International, based in Bogota, Colombia, for the commercialization of Fanapt ™ in Argentina.

1 Aug 2011

Nature Biotechnology publishes BGI, GT Life Sciences' study on CHO K1 genome

BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published July 31, 2011 online in Nature Biotechnology.

1 Aug 2011

Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia, during the 2011 American Heart Association's (AHA) Cardiovascular Scientific Sessions.

1 Aug 2011

New protein discovery could help develop intracellular biologic drugs

Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins-.

29 Jul 2011

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011

CytRx prices underwritten public offering of common stock

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has priced an underwritten public offering of 39,200,000 shares of common stock and warrants to purchase up to 39,200,000 shares of common stock at a combined public offering price of $0.52 per share and related warrant for gross proceeds of approximately $20.4 million.

27 Jul 2011

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen Corporation today reported results for the first quarter of fiscal year 2012, ended June 30, 2011.

27 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

Viewpoints: The effects of the debt debate; Medicare's birthday; N.Y. drug plan

In the scramble to cut the nation's debt burden, President Obama, congressional Democrats and even some Republicans have proposed squeezing money out of Medicare by changing the way it pays for prescription drugs.

27 Jul 2011

NeurOp receives NIH grant to support research program for ischemia

NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that the National Institutes of Health (NIH) has awarded the company a $3 million grant to support its research program for ischemia.

27 Jul 2011

BioWa, arGEN-X sign license agreement for POTELLIGENT Technology

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.

26 Jul 2011

Debiopharm, INC Research partner for clinical development programmes

INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group, a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership.

26 Jul 2011